Is TB-500 Legal in Washington State?

What TB-500 Actually Is

TB-500 is a synthetic, 17-amino-acid peptide fragment derived from thymosin beta-4, a naturally occurring protein encoded by the TMSB4X gene and found throughout human tissue. The full-length protein runs 43 amino acids; TB-500 corresponds to the actin-binding domain thought to drive most of thymosin beta-4's biological activity.

Mechanism at the cellular level

Thymosin beta-4 sequesters G-actin monomers, modulates the actin-cytoskeleton, and influences cell migration and differentiation. In animal models, exogenous thymosin beta-4 administration has been associated with accelerated wound closure, reduced cardiac fibrosis, and improved neuronal survival after ischemic injury. A 2010 study in Annals of the New York Academy of Sciences described thymosin beta-4 as "a multifunctional regenerative peptide" with activity across cardiac, corneal, and dermal tissues, though the authors noted that human translation remains unproven at therapeutic doses. [1]

What the human evidence actually shows

Human data are sparse. A Phase II trial (NCT01311518) evaluated thymosin beta-4 in 83 patients with non-healing venous stasis ulcers and showed modest improvement in wound area reduction versus placebo over 84 days, though the difference did not reach statistical significance. [2] No Phase III trial has been completed. The FDA has never approved a thymosin beta-4 product for any human indication. That absence of approval is the root of every downstream legal question.

The Federal Legal Framework

FDA drug-approval status

TB-500 has no New Drug Application (NDA), Biologics License Application (BLA), or Abbreviated NDA on file with the FDA. [3] Under the Federal Food, Drug, and Cosmetic Act (FD&C Act), any substance intended to diagnose, cure, treat, or prevent disease in humans is a "drug" and must either hold FDA approval or qualify for a specific exemption. Selling TB-500 as a finished drug product for human use without approval violates 21 U.S.C. 331. [4]

DEA scheduling

TB-500 does not appear on Schedules I through V of the Controlled Substances Act (CSA). [5] A prescriber does not need a separate DEA registration to write a prescription for it the way they would for testosterone or a benzodiazepine. Absence from the DEA schedule does not make a substance freely distributable; it simply means DEA enforcement authority does not apply.

503A individual compounding

Under 21 U.S.C. 353a, a state-licensed compounding pharmacy may prepare a drug for an identified patient without FDA pre-approval, provided the pharmacy follows United States Pharmacopeia (USP) standards, does not compound "essentially a copy" of a commercially available product, and uses bulk drug substances that appear on FDA's 503A bulks list. [6]

Thymosin beta-4 has been nominated to that list but has been placed in "Category 2," meaning the FDA has determined there is "insufficient information" to evaluate it for inclusion or it raises safety concerns that have not been resolved. [7] The FDA's current position is that Category 2 substances should not be used in 503A compounding until the evaluation is complete. Compounding pharmacies that use a Category 2 substance risk FDA warning letters and potential enforcement action.

503B outsourcing facilities

503B outsourcing facilities operate under stricter FDA oversight and must only use bulk substances that appear on the 503B bulks list or that are components of FDA-approved drugs. Thymosin beta-4 appears on neither list. [8] A 503B facility compounding TB-500 would be out of compliance with federal law.

The table below summarizes the legal pathways and their current status:

| Pathway | Federal Status | Available to Washington Patients? | |---|---|---| | FDA-approved drug | No approved product | No | | 503A compounding (patient-specific Rx) | Category 2 bulk; compounding unsupported by FDA | Legally risky; gray area | | 503B outsourcing facility | Not on 503B bulks list | No | | Research chemical (non-human label) | Legal to sell for non-clinical use | Not legal to administer to humans | | Import for personal use | FDA generally exercises discretion for personal imports of unapproved drugs; no guarantee | Uncertain; case-by-case |

Washington State's Role in the Legal Picture

What the Washington State Pharmacy Quality Assurance Commission does

The Washington State Pharmacy Quality Assurance Commission (PQAC) licenses pharmacies and pharmacists under RCW 18.64. [9] The PQAC incorporates federal compounding standards by reference rather than creating a parallel state-level approval process. In practice, a compounding pharmacy in Washington that compounds TB-500 for patients is exposed to the same Category 2 federal risk described above. The PQAC has not issued a Washington-specific statement permitting or banning TB-500 as of this writing. That silence does not create permission; it means state law defers entirely to federal frameworks.

Washington medical practice act

Under RCW 18.71, a licensed physician may prescribe drugs for legitimate medical purposes within their scope of practice. [10] Prescribing an unapproved substance is not automatically illegal under state law, but the prescriber takes on professional liability if the substance causes harm or if a board investigation finds the prescription lacked a legitimate clinical basis. The Washington Medical Commission (WMC) can impose disciplinary action, including license suspension, if a physician's prescribing falls outside the standard of care.

Telehealth rules in Washington

Washington RCW 18.71.095 explicitly permits out-of-state providers to prescribe for Washington patients via telehealth if the provider holds a Washington license or qualifies under an applicable interstate compact. [11] HealthRX providers licensed in Washington may write prescriptions for Washington-based patients following a proper patient-provider relationship, medical history review, and informed consent.

How a Washington Patient Can Legally Access TB-500

Step 1: Establish a legitimate clinical relationship

A prescription for any compounded peptide must originate from a genuine patient-provider encounter. A provider must document a clinical indication, review contraindications, and obtain informed consent. The WMC expects documentation of the rationale for off-label or compounded prescribing. [12]

Step 2: Identify a 503A-compliant compounding pharmacy

Despite the Category 2 designation, some 503A compounding pharmacies continue to prepare TB-500 on the basis that the FDA's Category 2 classification does not carry the force of a final rule. The legal risk is real. A Washington patient should ask any compounding pharmacy for documentation of their compliance posture and whether they have received FDA correspondence about their peptide compounding practices. The FDA's database of warning letters is publicly searchable at fda.gov. [13]

Step 3: Understand what "research chemical" suppliers are not

Dozens of online vendors sell TB-500 labeled "for research use only, not for human use." Purchasing from these suppliers and self-administering constitutes using an unapproved drug for human purposes, which violates federal law. [4] Washington's Consumer Protection Act (RCW 19.86) could also expose sellers to state-level liability if they market these products with implied human-use intent.

Step 4: Ask your provider about alternatives with clearer legal footing

Several peptides and biologics with overlapping indications have cleaner regulatory status. BPC-157 is in a similar gray area. PT-141 (bremelanotide) holds FDA approval under the brand name Vyleesi for hypoactive sexual desire disorder. [14] CJC-1295 and ipamorelin are also on the FDA's Category 2 list. A board-certified provider can help weigh risk-benefit against compounds with stronger safety and legality profiles.

Clinical Evidence: What the Trials Actually Show

Wound healing and tissue repair

The most consistent animal data come from murine and porcine wound models. A 2012 study in Wound Repair and Regeneration (N=32 rats) showed that topical thymosin beta-4 at 50 mcg/wound reduced wound area by 41% at day 7 compared to vehicle control (P<0.01). [15] These results have not been replicated at scale in humans.

Cardiac protection

A 2010 Nature publication demonstrated that thymosin beta-4 activated cardiac progenitor cells in infarcted mouse hearts, reducing infarct size by approximately 25% in treated animals. [16] The authors stated explicitly that "translation to human cardiac repair will require careful dose-finding and safety studies," none of which have been completed in registered Phase III trials as of mid-2025.

Neurological applications

A 2014 study in Journal of Neurochemistry found that thymosin beta-4 administered at 6 mg/kg in a rat stroke model reduced lesion volume by 35% at 7 days post-occlusion (P<0.05). [17] Once again, no human trials have advanced beyond pilot stages.

Anti-inflammatory signaling

Thymosin beta-4 downregulates NF-kB activity and reduces production of pro-inflammatory cytokines including TNF-alpha and IL-1beta in cell culture models. A 2016 review in International Immunopharmacology summarized 14 preclinical studies and noted "reproducible anti-inflammatory effects across tissue types, though the therapeutic window in humans remains undefined." [18]

Risks, Side Effects, and What Oversight Exists

Known adverse event profile

Because no Phase III human trials have been completed, the adverse event profile of TB-500 in humans is largely derived from case reports, small Phase I/II studies, and post-marketing observations from compounding pharmacy use. The Phase II venous ulcer trial (NCT01311518) reported no serious adverse events in the active arm, though the study was underpowered to detect rare harms. [2]

Theoretical risks

Thymosin beta-4 promotes angiogenesis and cell migration. Theoretically, these same mechanisms could accelerate growth in existing neoplasms. The 2016 International Immunopharmacology review flagged this concern explicitly, noting that "pro-angiogenic peptides warrant caution in patients with personal or family history of malignancy." [18] No clinical data confirm or refute this risk at compounded doses used in telehealth settings.

Quality and sterility concerns

Compounded injectable peptides carry risks of contamination, incorrect concentration, and improper sterility that are higher than FDA-approved parenteral products. USP Chapter 797 governs sterile compounding standards. [19] Patients should verify that any pharmacy supplying injectable TB-500 holds current 797 accreditation.

WADA and competitive athletes

WADA's 2024 Prohibited List places thymosin beta-4 under Section S4.2, "Other Growth Factors and Growth-Factor-Related Substances." [20] Any competitive athlete subject to WADA rules who uses TB-500, regardless of prescription status, faces a doping violation. Washington-based athletes competing under USADA jurisdiction should treat TB-500 as a banned substance regardless of its prescription legality.

What Washington Providers Should Document

A Washington physician or advanced practice provider prescribing a compounded TB-500 preparation should document: (1) the clinical indication and how standard-of-care options were considered first, (2) the patient's informed consent including the lack of FDA approval and Category 2 status, (3) the specific compounding pharmacy selected and its compliance documentation, and (4) a monitoring plan with defined endpoints. The WMC's 2019 guidance on non-traditional and integrative therapies states that "practitioners must be able to demonstrate a reasonable clinical basis for any prescribed therapy, documented in the medical record." [12]